All In Biotech

Drug Trial Radar · NCT02875834

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS, in Patients With Hyperkalemia-HARMONIZE Global

Last checked: Nov 20, 2026Latest source record: Aug 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 267 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

267

Actual

Start

Mar 3, 2017

Primary completion

Feb 14, 2018

Study completion Feb 14, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).

Conditions

  • Hyperkalemia

Interventions

  • Sodium Zirconium Cyclosilicate (ZS) 10gDrug

    Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)

  • Sodium Zirconium Cyclosilicate (ZS) 5gDrug

    Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.

  • Sodium Zirconium Cyclosilicate (ZS) 10gDrug

    Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.

  • PlaceboDrug

    Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Square Mean S-K Level on Days 8-29Time frame: Through 28-day randomized treatment study phase day 8-29.

Locations

45 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Chiba, Japan

  • Research Site

    Hanyu-shi, Japan

  • Research Site

    Hitachi-Naka, Japan

  • Research Site

    Ina-shi, Japan

  • Research Site

    Kanazawa, Japan

  • Research Site

    Koga-shi, Japan

  • Research Site

    Matsudo-shi, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Shimajiri-gun, Japan

  • Research Site

    Shizuoka, Japan

  • Research Site

    Toride-shi, Japan

  • Research Site

    Toyohashi, Japan

  • Research Site

    Yakushi, Japan

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Anyang-si, South Korea

  • Research Site

    Bucheon-si, South Korea

  • Research Site

    Bucheon-si, South Korea

  • Research Site

    Busan, South Korea

  • Research Site

    Cheongju-si, South Korea

  • Research Site

    Goyang-si, South Korea

  • Research Site

    Goyang-si, South Korea

  • Research Site

    Gwangju, South Korea

  • Research Site

    Hwaseong-si, South Korea

  • Research Site

    Incheon, South Korea

  • Research Site

    Incheon, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Suwon, South Korea

  • Research Site

    Uijeongbu-si, South Korea

  • Research Site

    Wŏnju, South Korea

  • Research Site

    Hualien City, Taiwan

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.